Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2014; 13(02): 142-143
DOI: 10.4103/1450-1147.139148
Case report

Late Aminophylline Reversal of Regadenoson Stress Testing in Patients with End Stage Renal Disease

Muaz Abudiab
Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, Arizona
,
Samuel Freiman
Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, Arizona
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

Regadenoson is a widely used and well-tolerated vasodilator agent for pharmacologic stress myocardial perfusing imaging. In patients at higher risk of adverse reactions such as those with end stage renal disease, it can be reversed with early administration of aminophylline. However, little is known about late administration of aminophylline. This case report describes the efficacy of late aminophylline use in patients with end stage renal disease. Possible explanations for the prolonged pharmacodynamic effect of regadenoson in this group are discussed.

Keywords

Aminophylline - myocardial perfusion imaging - pharmacologic stress - regadenoson


Publication History

Article published online:
23 May 2022

© 2014. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India